Joel Schlessinger M.D.

Joel Schlessinger MD authored an article along with other medical professionals on the use of AbobotulinumtoxinA in clinical practice. The article “Current Aesthetic Use of AbobotulinumtoxinA in Clinical Practice: An Evidence-Based Consensus Review,” is featured in the September issue of Aesthetic Surgery Journal.

A 13-person committee consisting of plastic surgeons, facial plastic surgeons and dermatologists discussed information about their beliefs and practices. The committee, of which one member was Joel Schlessinger MD, came to consensus on most issues.

The committee concluded the “field of effect” is difficult to measure and comparisons between different preparations of BoNT-A have created equivocal results.

It was also found that most adverse events are related to the trauma of the injection and are minor. The BoNT-A products are often used with other treatments such as fillers and resurfacing, but the committee did not agree on best practice with these treatments.

The study’s findings serve as a guide for medical practitioners as they apply the latest knowledge to provide their patients with the best care possible.

Joel Schlessinger MD offers BoNT-A injections in the form of BOTOX and Dysport. Joel Schlessinger MD is also one of the largest users of Dysport in the country. He has also conducted one of the largest ongoing clinical trials of this product at the Advanced Skin Research Center.

For more information on BoNT-A injections, set up a consultation today.